ME/CFS After Corona: Family Spends 100,000 Euros on Medication With No Success
Markus Leitner, a 51-year-old project manager in the semiconductor industry, walks silently beside his 17-year-old stepdaughter Lena through the fields near their home in Germany. It’s dark outside — the only time they can leave the house without triggering severe symptoms. For Lena and her mother Susanne, even ordinary light and sound are unbearable. Both suffer from myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), a debilitating neuroimmunological condition that developed after a coronavirus infection.
The family’s story, first reported by the Frankfurter Allgemeine Zeitung (FAZ), highlights the profound toll of long-term post-viral illness. Markus Leitner has become the primary caregiver for his wife and stepdaughter while maintaining his full-time job. He describes how the household has been transformed to accommodate their extreme sensitivity: doors are soundproofed, windows are blacked out, and daily life is reduced to short, quiet walks in the darkness.
According to the FAZ report, the Leitner family has spent over 100,000 euros on various medications and treatments in an attempt to alleviate symptoms. Despite this significant financial investment, there has been no meaningful improvement in either woman’s condition. The expenditures reflect the desperation many families face when confronting a disease with no approved curative treatment and limited understanding in mainstream medicine.
ME/CFS is characterized by profound exhaustion, cognitive dysfunction, unrefreshing sleep, and widespread pain that worsens after physical or mental exertion — a hallmark known as post-exertional malaise. Symptoms must persist for at least three months and cannot be explained by another medical condition. The illness often follows infections such as influenza, Epstein-Barr virus, or, increasingly, SARS-CoV-2.
The German Society for ME/CFS estimates that around 650,000 people in Germany live with the condition, though the actual number may be higher due to underdiagnosis. Globally, more than 40 million people may be affected, according to advocacy organizations. Studies suggest that up to one in four ME/CFS patients are severely impacted, often housebound or bedbound, and highly sensitive to light, noise, and touch.
Markus Leitner’s role as caregiver illustrates the broader societal burden of ME/CFS. He balances his responsibilities as a project manager with the constant demands of managing his family’s care — monitoring symptoms, minimizing environmental triggers, and advocating for medical attention in a healthcare system still struggling to recognize and treat the illness effectively.
The FAZ article notes that the Leitners’ experience is not isolated. Across Germany and beyond, families are navigating similar challenges after coronavirus infections triggered prolonged illness. While some individuals experience gradual improvement over time, many others, like Lena and Susanne Leitner, remain severely impaired years later, with treatments yielding little to no benefit.
Medical researchers continue to investigate the biological mechanisms behind ME/CFS, including immune dysregulation, autonomic nervous system dysfunction, and abnormal energy metabolism. However, no universally effective treatment has yet been identified. Symptom management — pacing, environmental control, and supportive care — remains the primary approach for most patients.
For Markus Leitner, the walks with Lena in the dark are more than just a necessity. they are moments of connection in an otherwise isolating routine. He speaks with her softly, sometimes in English to help her practice, discussing school friends and everyday topics — a fragile semblance of normalcy in lives otherwise defined by constraint.
As awareness of post-infection chronic illness grows, particularly in the wake of the pandemic, cases like the Leitners’ underscore the urgent need for better diagnostics, increased research funding, and accessible care pathways. Until then, families bear the weight of managing a condition that strips away energy, health, and often, the ability to participate fully in life.
The next checkpoint for the Leitner family, as with many affected by ME/CFS, remains uncertain. There is no known cure, and recovery timelines are highly variable. Continued symptom management and advocacy for greater medical recognition represent the most immediate path forward.
If you or someone you know is affected by ME/CFS or long-term post-viral illness, consider sharing this story to help raise awareness. Comments and discussions are welcome below.
